Seeking Alpha

AstraZeneca (AZN -3%) would consider $3-4B acquisitions and product deals of $500-$600M,...

AstraZeneca (AZN -3%) would consider $3-4B acquisitions and product deals of $500-$600M, although a large "disruptive" purchase is unlikely, says CEO Pascal Soriot following Q4 earnings. AZN, which is keeping buybacks on hold, won't raise its dividend for the first time in a decade. The firm is in the midst of a patent cliff, having lost exclusivity to Seroquel (schizophrenia) last year, and it's set to lose protection for Nexium (ulcers) and Crestor (cholestoral) in 2014 and 2016 respectively.
Comments (1)
  • Jbgoose
    , contributor
    Comments (1275) | Send Message
     
    Wouldn't a move into a firm like ENDP fit like a glove? I don't know anything but it puts them into the pain area and adds a generic product line plus is located close enough to draw from the vast worker pool of Philly Pharma World.
    31 Jan 2013, 10:33 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector